Related resources
Search for item elsewhere
University researcher(s)
Role of in vivo imaging of the central nervous system for developing novel drugs.
Rueger, M, Kracht, L, Hilker, R, Thiel, A, Sobesky, J, Winkeler, A, Thomas, A, Heneka, M, Graf, R, Herholz, KG, Heiss, W, Jacobs, A
Q J Nucl Med Mol Imaging. 2007;51( 2):164-81.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Use our list of Related resources to find this item elsewhere. Alternatively, request a copy from the Library's Document supply service.
Abstract
Over the past decade imaging technologies employed in clinical neurosciences have significantly advanced. Imaging is not only used for the diagnostic work-up of neurological disorders but also crucial to follow up on therapeutic efforts. Using disease-specific imaging parameters, as read-outs for the efficiency of individual therapies, has facilitated the development of various novel treatments for neurological disease. Here, we review various imaging technologies, such as cranial computed tomography (CT), magnetic resonance imaging (MRI) and spectroscopy (MRS), positron emission tomography (PET) and single-photon emission computed tomography (SPECT), with respect to their current applications in non-invasive disease phenotyping and the measurement of therapeutic outcomes in neurology. In particular, applications in neuro-oncology, Parkinson's disease, Alzheimer's disease, and cerebral ischemia are discussed. Non-invasive imaging provides further insights into the molecular pathophysiology of human diseases and facilitates the design and implementation of improved therapies.
Keyword(s)
Animals; Drug Design; Forecasting; Humans; diagnosis: Central Nervous System Diseases; diagnostic use: Radiopharmaceuticals; trends: Diagnostic Imaging; trends: Drug Delivery Systems; trends: Molecular Probe Techniques; trends: Nuclear Medicine